Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population Abstract The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: −22.6 (P < .001), −22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations. Submitted April 8, 2011. Accepted June 20, 2011. © 2011 by The American Society of Hematology

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population / Fabio, Efficace; Michele, Baccarani; Massimo, Breccia; Giuliana, Alimena; Gianantonio, Rosti; Francesco, Cottone; Giorgio Lambertenghi, Deliliers; Claudia, Baratè; Antonella Russo, Rossi; Giuseppe, Fioritoni; Luigia, Luciano; Diamante, Turri; Bruno, Martino; Francesco Di, Raimondo; Melissa, Dabusti; Micaela, Bergamaschi; Leoni, Pietro; Maria Pina, Simula; Luciano, Levato; Stefano, Ulisciani; Dino, Veneri; Siimona, Sica; Alessandro, Rambaldi; Marco, Vignetti; Franco, Mandelli. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 118:17(2011), pp. 4551-4560.

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

LEONI, Pietro;
2011-01-01

Abstract

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population Abstract The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: −22.6 (P < .001), −22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations. Submitted April 8, 2011. Accepted June 20, 2011. © 2011 by The American Society of Hematology
2011
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/75154
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 205
  • ???jsp.display-item.citation.isi??? 186
social impact